Geral Imunohistoquímica Mama

A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

Escrito por Carla Brito Lopes

Immunohistochemistry is increasingly used in the assessment of markers for breast cancer prognosis. Semiquantitation is frequently desirable but, other than by the use of image analysis, the approaches currently in use are cumbersome. The most common method used is the H-score which takes into consideration the staining intensity in conjunction with the percentage of cells staining positively in breast carcinoma tissue.

A “quickscore” has been developed which dispenses with the need to count individual cells. The quantitative biochemical Abbott enzyme immunoassay (EIA) and the Dako immunohistochemical assay (IHA) incorporating a semiquantitative H-score, have been used as standards against which the IHA quickscore for the semiquantitation of oestrogen receptor expression was tested. A good correlation was found between the quickscore and the EIA, which was as good as that between the H-score and EIA. The quickscore is a valid approach and there is no advantage in using the more rigorous H-score. A positive cut off quickscore of > or = 3 has been suggested.


Article first published: 17 Jan 1995
DOI: Non aplicable
Download: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC502883/pdf/jclinpath00234-0090.pdf

Citation: Detre S, Saclani Jotti G, Dowsett M. J Clin Pathol. Sep 1995; 48(9): 876–878.

Copyright: © BMJ Group.

From: US National Library of Medicine <http://www.nlm.nih.gov/> – National
Institutes of Health <http://www.nih.gov/>. http://www.ncbi.nlm.nih.gov/pubmed/25078555.
Disclaimer: http://www.ncbi.nlm.nih.gov/About/disclaimer.html

Sobre o autor

Carla Brito Lopes

Carla nasceu a 14 de Fevereiro de 1977 em Viana do Castelo. Completou o bacharelato em Anatomia Patológica, Citológica e Tanatológica na ESTES-Porto em 1998 e licenciou-se em 2001 pela Escola Superior de Tecnologia da Saúde em Lisboa. Concluiu a certificação em Laboratory Management pela ASCP (American Association of Clinical Pathology) em Setembro de 2016.
Actualmente encontra-se a frequentar mestrado em Genética Molecular e Biomedicina na Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa.